My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are not the best first option for most people. Try appeal routes, manufacturer help, or FDA‑approved alternatives before using compounded products. If you’re still considering compounding, only do so after careful checks (see below).

Why compounded GLP‑1s are risky

• Not FDA approved: potency, purity, sterility and stability aren’t guaranteed the way brand drugs are.
• Infection/contamination risk with injectable compounding (there have been serious outbreaks in the past).
• Insurance almost never covers compounded versions — you’ll likely pay out of pocket.
• Limited liability/support: no manufacturer safety program or established pharmacovigilance.

What to try first (recommended actions)

1. Appeal the denial
   • Ask your prescriber to submit a prior‑authorization appeal or a peer‑to‑peer review. Provide clinical documentation (BMI, comorbidities, prior weight‑loss attempts, labs). Appeals are often successful.
2. Check manufacturer assistance and copay programs
   • Novo Nordisk (Wegovy) and Eli Lilly (Zepbound/Mounjaro) offer patient support, co‑pay savings or patient assistance programs that can substantially lower cost for eligible patients. Contact the company’s patient support line or your prescriber’s office to enroll.
3. Ask about other FDA‑approved options
   • Saxenda (liraglutide) — FDA‑approved for weight management (different dosing but established safety record).
   • Zepbound (tirzepatide) and Mounjaro (tirzepatide) — tirzepatide is available from Eli Lilly; Zepbound is approved for chronic weight management (discuss availability/cost with prescriber).
   • Ozempic (semaglutide) or Rybelsus (oral semaglutide) — approved for diabetes but sometimes used under clinician guidance; insurance coverage may differ.
   • Non-GLP‑1 weight medications: Qsymia (phentermine/topiramate), Contrave (naltrexone/bupropion), Xenical/Alli (orlistat) — these may be better covered by insurance.
   • Your clinician can recommend which alternative fits your medical profile.
4. Look for lower legitimate prices
   • Use price‑comparison/coupon services such as GoodRx to check retail savings.
   • Specialty pharmacies (CVS Specialty, Accredo, Optum Specialty) may be able to help with access and prior‑auth navigation.
5. Consider clinical trials
   • Search clinicaltrials.gov for trials of GLP‑1 or tirzepatide weight‑loss studies — participants may receive medication at no cost.

If you’re considering compounded GLP‑1s (only after exhausting other options)

• Only use a reputable, licensed compounding pharmacy that follows sterile USP <797> standards. Ask for:
  • Evidence of state board licensure and sterile compounding certification.
  • Certificate of analysis, lot testing, and expiration/stability data.
  • Written info on sterility testing and storage/handling.
• Discuss risks with your prescriber and get written informed consent.
• Understand your insurer almost certainly won’t cover it.

If you’d like, I can:

• Help draft an appeal/prior‑authorization letter your clinician can use (I can include the clinical points insurers typically want).
• Look up patient assistance/savings program phone numbers and links for Wegovy or Zepbound (tell me your country).
• Walk through what to ask a compounding pharmacy if you end up considering that route.

Tell me which country you’re in and why Wegovy was denied (medical reason on the denial) and I’ll tailor the next steps.